Chiou Yi-You, Tseng Hsiuo-Shan, Chiang Jen-Huey, Hwang Jen-I, Chou Yi-Hong, Chang Cheng-Yen
Department of Radiology, Taipei Veterans General Hospital, and School of Medicine, National Yang-Ming University, Taipei, Taiwan.
J Formos Med Assoc. 2005 Oct;104(10):738-43.
The placement of metallic stents is now a well-established method in the management of malignant biliary obstruction. This study evaluated the long-term clinical efficacy of percutaneous transhepatic insertion of metallic stents in the management of malignant biliary obstruction.
From January 1999 to December 2002, 102 consecutive patients with malignant biliary obstruction were treated with percutaneous transhepatic placement of metallic stents at a medical center in Taipei. The level of obstruction was at the hepatic hilum in 44 patients, and common bile duct (CBD) in 58 patients. Memotherm stents were used in 78 patients and Wallstents in 38. Among the 44 patients with hilar obstruction, 30 received a single stent and 14 received bilateral stents. Among the 58 patients with CBD obstruction, the stents were placed across the ampulla of Vater in 27. Patient survival rates and stent patency rates were compared using the Kaplan-Meier method.
Placement of stents was successful in all patients. The mean (range) serum bilirubin level before, 1 week after, and 1 month after stent insertion was 15.1 mg/dL (4.2-32.4 mg/dL), 7.8 mg/dL (0.5-19.4 mg/dL), and 1.8 mg/dL (0.2-8.2 mg/dL), respectively. The mean survival in all patients was 66.0 weeks (1-130 weeks) and the mean stent patency period (MSPP) in all patients was 59.9 weeks (1-130 weeks). The MSPP was 71.4 versus 49.9 weeks in hilar type versus CBD type patients (p = 0.047). The MSPP was 53.9 versus 73.0 weeks in patients who received Memotherm stents versus Wallstents (p = 0.115). In the hilar obstruction group, the MSPP was 82.1 versus 58.0 weeks in patients receiving bilateral versus a single stent (p = 0.039). In the CBD obstruction group, the MSPP was 46.3 versus 45.5 weeks in stents placed across versus not placed across the ampulla of Vater (p = 0.338).
The efficacy and patency period of percutaneous transhepatic insertion of metallic stents in the management of malignant biliary obstruction is satisfactory in the relief of obstructive jaundice. Both types of metallic stents performed well in relieving malignant biliary obstruction. Bilateral stenting was more effective than single stenting in treating patients with hilar obstruction. In patients with CBD obstruction, no significant difference in the stent patency period was found between stents placed across or not across the ampulla of Vater.
金属支架置入术现已成为治疗恶性胆管梗阻的一种成熟方法。本研究评估经皮经肝置入金属支架治疗恶性胆管梗阻的长期临床疗效。
1999年1月至2002年12月,台北一家医疗中心对102例连续性恶性胆管梗阻患者行经皮经肝金属支架置入术。梗阻部位在肝门部44例,胆总管(CBD)58例。78例患者使用Memotherm支架,38例使用Wallstent支架。在44例肝门部梗阻患者中,30例置入单个支架,14例置入双侧支架。在58例CBD梗阻患者中,27例支架跨过Vater壶腹置入。采用Kaplan-Meier法比较患者生存率和支架通畅率。
所有患者支架置入均成功。支架置入前、置入后1周和1个月时血清胆红素平均(范围)水平分别为15.1mg/dL(4.2 - 32.4mg/dL)、7.8mg/dL(0.5 - 19.4mg/dL)和1.8mg/dL(0.2 - 8.2mg/dL)。所有患者平均生存时间为66.0周(1 - 130周),所有患者平均支架通畅期(MSPP)为59.9周(1 - 130周)。肝门部梗阻型患者与CBD梗阻型患者的MSPP分别为71.4周和49.9周(p = 0.047)。使用Memotherm支架与Wallstent支架患者的MSPP分别为53.9周和73.0周(p = 0.115)。在肝门部梗阻组,接受双侧支架与单个支架患者的MSPP分别为82.1周和58.0周(p = 0.039)。在CBD梗阻组,支架跨过与未跨过Vater壶腹置入患者的MSPP分别为46.3周和45.5周(p = 0.338)。
经皮经肝置入金属支架治疗恶性胆管梗阻在缓解梗阻性黄疸方面疗效及通畅期令人满意。两种类型的金属支架在缓解恶性胆管梗阻方面均表现良好。双侧支架置入在治疗肝门部梗阻患者中比单个支架置入更有效对于CBD梗阻患者,支架跨过或未跨过Vater壶腹置入时,支架通畅期无显著差异。